Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Merck Continues to Thin Out
- Derek Lowe submits: As everyone knows, Merck MRK announced some big job cuts Wednesday – 7,200 positions, around 10% of the work force. It’s worth looking at the details of these, because they differ a bit from what’s been going on at some other companies. For one thing, the...
- External links 2008-10-23
- Wyeth Cuts Back Too: Are New Opportunities Being Created?
- Derek Lowe submits: So Wyeth WYE is cutting back on its therapeutic areas as well. According to that Bloomberg story, they're going to focus on oncology, inflammation, neuroscience, vaccines, metabolic diseases and muscular-skeletal disorders. That's still a pretty wide swath of territory, but note what it leaves out: cardiovascular...
- External links 2008-10-30
- Pension Fund Thinks Lilly / Imclone Deal Too Cheap
- Derek Lowe submits: I honestly didn’t think I’d ever get the chance to write about Imclone IMCL again. But never say never! It turns out that a pension fund, the State Retirement System of Massachusetts, is suing to block the Lilly LLY acquisition – because, hold on to your...
- External links 2008-10-31
- Not Running Out to Buy Shares in Pfizer
- Derek Lowe submits: I shouldn't pick on Jeff Kindler, because I wouldn't want to be CEO of Pfizer PFE, not the least little bit. But he gave an interview recently to the Financial Times, who asked him naturally about the Lipitor patent expiration. His answer: We're facing a...
- External links 2008-11-03
- AstraZeneca's Cardiovascular Drug: Risks Up, Risks Down
- Derek Lowe submits: AstraZeneca AZN took a pretty big risk in running a trial as big as the JUPITER one, but it seems to have paid off for them. As everyone has been reading, it appears that their Crestor rosuvastatin lowers the risk of cardiovascular events in patients with...
- External links 2008-11-10
- Wyeth vs. Conte: Are Big Pharmas Now Liable for Generics?
- Derek Lowe submits: There was a legal ruling last week in California that we’re going to hear a lot more of in this business. Conte v. Wyeth WYE. This case involved metaclopramide, which was sold by Wyeth as Reglan before going off-patent in 1982. The plaintiff had been prescribed...
- External links 2008-11-18
- Did Novartis's Research Site Turn Out as Planned?
- Derek Lowe submits: I know that it’s not necessarily fair to drag out old press releases, but let’s do it anyway. Many readers will remember a few years back when Novartis NVS was making its big research move into Cambridge, renovating the old Necco candy building and hiring like...
- External links 2008-11-19
Additional Resources
- The Lilly-ImClone Deal Worst-Case Scenario
- Some people were apparently surprised that Eli Lilly has emerged as the mystery $70-a-share bidder for ImClone. BNET readers weren't among them, as I noted a few days ago this is just the kind of bold plan that CEO John Lechleiter seems to favor. Interestingly, ImClone's stock...
- Blog posts 2008-10-02
- << Previous
- page 1 of 1
- Next >>
Presented by American Express